FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:256-257 January 16, 2003 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Becker, R. C. Related Article by Hurlen, M. PubMed Citation

To the Editor: Hurlen et al. (Sept. 26 issue)¹ showed that warfarin with or without aspirin, as compared with aspirin alone, was associated with a reduction in the risk of the composite end point of death, nonfatal myocardial infarction, or embolic stroke in patients with myocardial infarction but did not establish its clinical relevance. They did not assess the implications of the components of the end point for patients. As compared with aspirin alone, the absolute reduction in the rate of nonfatal myocardial infarction with warfarin alone was 0.6 percent per year and with warfarin plus aspirin was 1.1 percent. . . . [Full Text of this Article]

This article has been cited by other articles:

• Rothberg, M. B., Celestin, C., Fiore, L. D., Lawler, E., Cook, J. R. (2005). Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit. ANN INTERN MED 143: 241-250 [Abstract] [Full Text]